伴有抗凝血因子H IgM的边缘区淋巴瘤和非典型溶血尿毒综合征经奥多妥单抗成功治疗 - Suppr

Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab.

作者信息

Ardissino Gianluigi, Angelillo Piera, Mancuso Maria Cristina, Griffini Samantha, Grovetti Elena, Porcaro Luigi, Ria Thomas, Marktel Sarah, Peyvandi Flora, Luminari Stefano, Ferreri Andrés J M, Merli Michele, Cugno Massimo

机构信息

Centro per la Cura e lo Studio della Sindrome Emolitico-Uremica, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.

Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan.

出版信息

Haematologica. 2025 Sep 1;110(9):2235-2239. doi: 10.3324/haematol.2025.287532. Epub 2025 May 15.

DOI:10.3324/haematol.2025.287532

PMID:40371898

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12399954/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/309d/12399954/7ef12cac1a7c/1102235.fig1.jpg

相似文献

Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab.伴有抗凝血因子H IgM的边缘区淋巴瘤和非典型溶血尿毒综合征经奥多妥单抗成功治疗

Haematologica. 2025 Sep 1;110(9):2235-2239. doi: 10.3324/haematol.2025.287532. Epub 2025 May 15.

Genetic Atypical Hemolytic-Uremic Syndrome遗传性非典型溶血性尿毒症综合征

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.肿瘤内免疫细胞亚群的分子评估及奥妥珠单抗（一种 CD20×CD3 双特异性抗体）治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者耐药的潜在机制。

J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338.

IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.非典型溶血性尿毒症综合征中针对补体因子H的IgM自身抗体

J Am Soc Nephrol. 2021 May 3;32(5):1227-1235. doi: 10.1681/ASN.2020081224. Epub 2021 Mar 12.

Comprehensive genetic analysis and genotype-phenotype correlations in pediatric patients with atypical hemolytic uremic syndrome.非典型溶血尿毒综合征儿科患者的综合基因分析及基因型-表型相关性研究

Pediatr Nephrol. 2025 Jun 6. doi: 10.1007/s00467-025-06814-1.

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.在滤泡性淋巴瘤中，epcoritamab与化疗免疫疗法、mosunetuzumab或odronextamab的间接比较。

Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274.

A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.妊娠相关性非典型溶血尿毒综合征/补体介导的血栓性微血管病的病例叙述性综述。

Kidney Int. 2024 May;105(5):960-970. doi: 10.1016/j.kint.2023.12.021. Epub 2024 Feb 24.

Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome - a case-series report.补体C5抑制剂依库珠单抗在感染相关性溶血尿毒综合征患者中的应用——病例系列报告

BMC Pediatr. 2025 Mar 11;25(1):181. doi: 10.1186/s12887-025-05546-3.

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.妊娠早期非典型溶血性尿毒症综合征经依库珠单抗成功治疗。

Exp Hematol Oncol. 2017 Jan 13;6:4. doi: 10.1186/s40164-017-0064-7. eCollection 2017.

Approach to the prevention of atypical hemolytic uremic syndrome recurrence using eculizumab in a pregnant kidney transplant recipient with complement factor H gene mutation: a case report and literature review.在一名患有补体因子H基因突变的妊娠肾移植受者中使用依库珠单抗预防非典型溶血性尿毒症综合征复发的方法：病例报告及文献综述

J Nephrol. 2025 Jul 11. doi: 10.1007/s40620-025-02342-1.

本文引用的文献

Cutting-edge approaches to B-cell depletion in autoimmune diseases.自身免疫性疾病中 B 细胞耗竭的前沿方法。

Front Immunol. 2024 Oct 9;15:1454747. doi: 10.3389/fimmu.2024.1454747. eCollection 2024.

BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.用于自身免疫性疾病的靶向BCMA的T细胞衔接器疗法

N Engl J Med. 2024 Sep 5;391(9):867-869. doi: 10.1056/NEJMc2408786.

CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.CD19 CAR T 细胞疗法治疗自身免疫性疾病 - 附随访的病例系列。

N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917.

Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.非典型溶血尿毒综合征的转归：触发因素和补体异常在 C5 抑制反应中的作用。

J Nephrol. 2024 May;37(4):1017-1026. doi: 10.1007/s40620-023-01873-9. Epub 2024 Jan 27.

Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura.获得性血栓性血小板减少性紫癜患者的补体激活与肾功能障碍

Blood. 2023 May 4;141(18):2278-2282. doi: 10.1182/blood.2022018644.

Eculizumab treatment in atypical hemolytic uremic syndrome: correlation between functional complement tests and drug levels.依库珠单抗治疗非典型溶血性尿毒症综合征：功能性补体检测与药物水平之间的相关性

J Nephrol. 2022 May;35(4):1205-1211. doi: 10.1007/s40620-021-01187-8. Epub 2022 Jan 11.

IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.非典型溶血性尿毒症综合征中针对补体因子H的IgM自身抗体

J Am Soc Nephrol. 2021 May 3;32(5):1227-1235. doi: 10.1681/ASN.2020081224. Epub 2021 Mar 12.

The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.不同部位黏膜相关淋巴组织淋巴瘤的谱：生物学和治疗相关性。

Blood. 2016 Apr 28;127(17):2082-92. doi: 10.1182/blood-2015-12-624304. Epub 2016 Mar 17.

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.停止依库珠单抗维持治疗非典型溶血尿毒综合征：10 例报告。

Am J Kidney Dis. 2014 Oct;64(4):633-7. doi: 10.1053/j.ajkd.2014.01.434. Epub 2014 Mar 19.

Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.抗因子 H 自身抗体相关性溶血尿毒综合征：自身免疫性溶血尿毒综合征 H 因子形式的文献综述。

Semin Thromb Hemost. 2010 Sep;36(6):633-40. doi: 10.1055/s-0030-1262885. Epub 2010 Sep 23.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献